06:50 PM EDT, 08/06/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

MCK released Q1 FY 26 results above consensus, with adjusted EPS of $8.26 (+4.8% Y/Y) topping the $8.15 expectation. Sales of $97.8B (+23.4% Y/Y) exceeded the $96.3B consensus. Continued strength in North American pharma volumes drove results, with U.S. Pharma sales up ~25% to ~$90B on Rx volume growth. GLP-1 revenues rose ~38% Y/Y to ~$12.1B. Adjusted EBIT margin compressed to 1.46% from 1.65%, reflecting the low-margin nature of GLP-1 drug distribution. MCK raised FY 26 guidance with a 0.5% increase to the EPS midpoint amid higher profit expectations for both U.S. Pharma and International. Guidance also reflects accretion from the recently announced Norway operations sale, completing the company's European divestitures. The company also announced another 15% dividend increase (fourth consecutive of ~15%), marking the ninth consecutive year of annual increases and reflecting strong FCF generation, in our view. MCK guides for ~$2.5B of share repurchases in FY 26.